Enforced expression of miR-34a inhibited prostate cancer stem cells and metastasis by directly repressing CD44, indicating that miR-34a is a key negative regulator of prostate CSCs and could be a novel therapeutic agent against prostate cancers [11]. This evidence concerns the gene CD44 and prostate cancer.